The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.

ABSTRACT: Medulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic strategies are needed to increase survival rates and to reduce treatment-related toxicity. We performed a noncomprehensive targeted review of the current clinical trial landscape and literature to summarize innovative treatment options for non-WNT/non-SHH medulloblastoma. A multitude of new drugs is currently evaluated in trials for which non-WNT/non-SHH patients are eligible, for instance immunotherapy, kinase inhibitors, and drugs targeting the epigenome. However, the majority of these trials is n

SUBMITTER: Ghasemi DR 

PROVIDER: S-EPMC8833659 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature